NASDAQ · CYDY
Healthcare · Biotechnology
$0.21
Up+$0.01 (+2.44%)
Updated Sep 24, 2026, 3:18 AM
SID Score
4.5/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
CYDY does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning CYDY.
CYDY research
Filterable reporting and market headlines.
Filters are reflected in the page URL for sharing and back-button support.
2 matching articles.
Yahoo · Sep 19, 2026
CytoDyn (OTCMKTS:CYDY) Chief Financial Officer Robert E. Hoffman outlined the company’s clinical-development plans for leronlimab, a CCR5-targeting humanized monoclonal antibody being studied in metastatic colorectal cancer, triple-negative breast cancer and other solid tumors. Speaking at the Life
Yahoo · Sep 18, 2026
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.comNEW YORK, Sept. 18, 2026 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, announced the presentations from the September 17th Life Sciences Virtual Investor Forum are available for on-demand viewing. The event featured live presentations from executives representing innovative clinical-stage and commercial companies across the life sciences sector. REGIS
The latest Smart Investors Daily articles mentioning CYDY.
